Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

Just days after the FDA approved AstraZeneca and Daiichi Sankyo's Enhertu for a potentially lucrative new use, the regulatory has now cleared a diagnostic test that could help unlock the drug's ...

For more than two years, the stock market has been virtually unstoppable. Last year, the iconic Dow Jones Industrial Average (DJINDICES: ^DJI), broad-based S&P 500 (SNPINDEX: ^GSPC), and ...

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

Equity ETFs kicked off 2025 with subdued flows as more money went into fixed income funds. According to a recently released FactSet report, inflows to U.S. equity ETFs nearly halved by the end of ...

Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

U.S. Bancorp Dep. Pfd. (Rep. 1/1000th Non-Cum. Perp. Pfd. Series K) 1.15% U.S. Bancorp Dep. Pfd. (Rep. 1/1000th Perp. 3.75% Pfd. Series L) 0.86% U.S. Bancorp Dep. Pfd ...

If you are a teacher, professor or instructor of students over 16 years of age looking to play a free stock market game with your class, you can use these documents to get started. Yes.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The best stock screeners for day trading like Benzinga Pro, Interactive Brokers and TradingView help you slice through thousands of stocks based on your criteria, making spotting those golden trad ...